InsidersTradesSigma
Belite Bio, Inc. Stock: price and management transactions · United States · SEC (Form 4)
SEC:belite-bio-inc-92b37aUS·SEC (Form 4)
Follow the Belite Bio, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on US US, under the authority of SEC (Form 4). The latest transaction was reported on 18 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Dr. Hendrick P. Scholl. The full history is openly available.
2
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
10Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 18 June 2026
Declarations2 total
10,000 shares@ US$148.34100.0% of flowAmerican Depositary Shares, each representing one ordinary shareSEC144:0001968582-26-000631
10,000 shares@ US$144.24American Depositary Shares, each representing one ordinary shareSEC144:0001968582-26-000623
2 of 2 declarations
About Belite Bio, Inc.
Belite Bio, Inc. is a biopharmaceutical company focused on developing treatments for retinal diseases. It is listed on the NASDAQ under the ticker symbol BLTE.